HERV-derived epitopes represent new targets for T-cell-based immunotherapies in ovarian cancer

20253 citationsJournal Articlegold Open Access

Authors

These results provide the preclinical rationale for developing T-cell-based approaches against HERV-K-derived epitopes in ovarian cancer.

Good health and well-being

Published in: Journal for ImmunoTherapy of Cancer

Volume 13, Issue 8, pp. e010099-e010099

Field-Weighted Citation Impact: 2.49